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Background: Nuna Kadugu (NK), a Siddha medicine prepared from leaves and fruits of Morinda Pubescens, used for
the treatment of various skin diseases. Though NK has been widely used for several decades, no scientific report
was available on its safety. Present study was undertaken to demonstrate the oral toxicity of NK in Sprague
Dawley rats.
Methods: Acute and 28-day repeated oral toxicity studies were performed following OECD test guidelines 423 and
407, respectively, with minor modifications. In acute oral toxicity study, NK was administered at 2000mg/kg b.wt.,
p.o and animals were observed for toxic signs at 0, 0.5, 1, 4, 24 h and for next 14 days. Gross pathology was
performed at the end of the study. In repeated dose, the 28- day oral toxicity study, NK was administered at 300,
600 and 900 mg/kg b.wt./p.o/day. Two satellite groups (control and high dose) were also maintained to determine
the delayed onset toxicity of NK. Animals were observed for mortality, morbidity, body weight changes, feed and
water intake. Haematology, clinical biochemistry, electrolytes, gross pathology, relative organ weight and
histopathological examination were performed.
Results: In acute toxicity study, no treatment related death or toxic signs were observed with NK administration. In
the repeated dose study, no significant differences in body weight changes, food / water intake, haematology,
clinical biochemistry and electrolytes content were observed between control and NK groups. No gross
pathological findings and difference in relative organ weights were observed between control and NK treated rats.
Histopathological examination revealed no abnormalities with NK treatment.
Conclusion: Acute study reveals that the LD50 of NK is greater than 2000mg/kg, b.wt. in fasted female rats and can
be classified as Category 5. 28-day repeated oral toxicity demonstrates that the No Observed Adverse Effect Level of
NK is greater than 900 mg/kg b.wt./day, p.o in rats. There were no delayed effects in NK satellite group. In
conclusion, NK was found to be non-toxic in the tested doses and experimental conditions.
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Skin diseases are one among the major diseases for
which traditional medicines are preferred and largely uti-
lized. Vitiligo or leucoderma is characterized by skin de-
pigmentation resulting in the appearance of patches due
to melanocyte dysfunction. The exact pathogenesis of
vitiligo remains unclear and is likely to be multifactorial,
suggesting the involvement of autoimmune and genetic* Correspondence: nisceftpublications@gmail.com
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Though the prevalence of vitiligo varies significantly
with age, there is no significant difference seen between
genders [2]. The incidence of vitiligo is 0.1-2% world-
wide and 0.25 - 2.5% in India [2,3]. Vitiligo is termed as
“Venpulli Noi” or “Venpadai” in Siddha system of medi-
cine. On the basis of three vital humours, Siddha system
classifies vitiligo (venpadai) as “Vatha venpadai”, “Pitha
venpadai” and “Kaba venpadai”. Another type of vitilgo
is called “Megha venpadai” (through sexual transmis-
sion) in the Siddha pathophysiology of vitiligo.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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known as Indian Mulberry, is an evergreen shrub or small
tree of 5–10 m tall and a promising medicinal plant used
widely by the Siddha practitioners [4]. It is an indigenous
plant of Tamilnadu and is called “Nuna” in Tamil. Ethno-
medically, the bark of Nuna is well known for its use in
the treatment of eczema, fever due to primary complexes,
ulcers and glandular swellings; whilst the leaves are useful
in digestive disorders (Mantham) in children and in ven-
ereal diseases [5]. Fruit extract of Nuna is reported to pos-
sess antimicrobial, antifungal, wound healing, antidiabetic
and hepatoprotective activities [4,6,7].
Pattai karappanodu paarachileshma suram
Ottinindra pun kranthi ottunkaan – Mattalarai
Yenthu Nunaavin ilai mantham theerthu nalla
Kaanthi tharu meham adunkaan
- Agathiyar Gunavakadam
The meaning of this Siddha verse is that the bark of
Nuna is useful in the treatment of eczema (karappan),
fever (Iyya suram), ulcers, and tumours/swellings (kranthi).
Leaves relieve indigestion (mantham), venereal diseases
(Mega noikal) and also give luster to skin. Medicinal
preparations using Nuna leaves and gingelly oil called
as Nuna kadugu (internal use) and Nuna thailam (ex-
ternal application) are indicated for the treatment of
vitiligo [8].
An open label clinical study (40 participants) with Nuna
kadugu (NK) reveals its evidence-based use in the treat-
ment of vitiligo (our unpublished data), however there is
no scientific report to evaluate potential human toxicity.
Hence, the present study was undertaken to establish the
toxicity profile of NK in experimental animals which will
render strong evidence for its safety in clinical use.Methods
Chemicals and reagents
Clinical diagnostic kits were purchased from M/s.
Accurex Biomedical Pvt. Ltd., India. All other chemicals
and reagents used were of analytical grade.Plant material
Leaves and fruits of Morinda pubescens (Nuna) were
procured from M/s. Arogya Health Care Pvt. Ltd., Chen-
nai, traditional herbs and raw drugs dealer. Materials
were authenticated by Dr. Sasikala Ethirajulu, Assistant
Director (Pharmacognosy), Siddha Central Research In-
stitute, Chennai, India. Voucher specimen of the herbar-
ium (NIS/SM-Dept/herbarium/2010/Nuna/RAM) were
prepared and stored in the Department of Sirappu
Maruthuvam, National Institute of Siddha, Chennai, for
future references.Preparation of medicine
The leaves and fruits of Morinda Pubescens (Nuna) were
freed from earthy matters, decayed leaves, fruits and
washed with water. They were chopped into small pieces
and ground into a paste form called “Karkam” (as per
the classical Siddha literature) by adding sufficient quan-
tity of water in “Kalvam” (a traditional grinding tool
made of stone). Karkam was weighed and boiled with
equal weight of unrefined gingelly oil till it disintegrated
to the size of mustard seeds called as “Nuna Kadugu”. It
was filtered to remove the oil now called “Nuna Thai-
lam” which was later cooled and stored. Nuna Kadugu
was blotted, using butter paper, multiple times to re-
move the last traces of oil.
Standardisation of nuna kadugu
Phytochemicals
Preliminary phytochemical qualitative screening of NK
was performed using standard method [9]. Phytochem-
ical constituents such as phenolic compounds, reducing
sugars, flavones, glycosides, saponins, alkaloids, anthro-
quinones, proteins and tannins were qualitatively ana-
lyzed. Total phenols were tested by reacting NK with
few drops of alcoholic ferric chloride solution. Flavones
were tested by adding 10% sodium hydroxide solution or
ammonia with NK. Glycosides were tested by mixing
NK with a little anthrone on a watch glass and a drop of
concentrated sulphuric acid and warming gently over
water bath. Saponins were tested by shaking NK with
water for frothing test. NK was tested for the presence
of reducing sugars, alkaloids, anthraquinones, quinones,
protein and tannins by reacting with Fehling’s solution A
and B, acetic acid followed by Draggendroff ’s reagent,
aqueous ammonia or caustic soda, sodium hydroxide,
few drops of biuret reagent and basic lead acetate solu-
tion respectively.
Content of total phenols in NK was determined by the
method proposed in earlier method [10], Briefly, 1.25ml
of 1:10 diluted Folin’s Ciocalteau reagent and 1ml of
7.5% Na2CO3 were added to tubes containing 0.25 ml of
the NK (1mg/ml). The mixture was allowed to stand for
30 min at 37°C and the colour intensity was measured at
765 nm. Total phenol content was expressed in terms of
%w/w. Tannins was performed as per the earlier method
[11]. 0.2ml of the NK (0.5mg/ml) was made up to 0.5ml
with methanol. 0.25 ml of Folin’s phenol reagent and 2.5
ml of 1% sodium carbonate were pipetted into all the
tubes. The tubes were incubated for 5 minutes at room
temperature. 0.25 ml of Folin’s phenol and 2.5 ml of 1%
sodium carbonate serves as blank. The blue colour
developed was measured at 640 nm. The content was
expressed in %w/w. Finally flavonoid content of NK was
employed using aluminium chloride colorimetric
method [12]. To 1ml of NK (1mg/ml), 0.1 ml of 10%
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2.8 ml of distilled water were added. The tubes were
incubated at room temperature for 30 min. The absorb-
ance was measured at 415 nm. The content was
expressed in %w/w.
Aflatoxins and heavy metals
Aflatoxins (B1, B2, G1 and G2) using LC-MS technique
and heavy metals (lead, cadmium, mercury and arsenic)
contents using atomic absorption spectroscopy were also
determined following standard protocols.
HPTLC fingerprint of NK
High Performance Thin Layer Chromatography
(HPTLC) fingerprint of NK was developed using Silica
gel GF254 as stationary phase and toluene: ethyl acetate:
formic acid: acetic acid (30:30:8:2.5) as mobile phase.
The plates were developed in twin trough chamber and
scanned at 254 nm in TLC III scanner.
Experimental animals husbandry
Male and female Sprague–Dawley rats, (130-160g)
obtained from Central Animal Facility, Sri Ramachandra
University, Chennai, India were used for the study. Ani-
mals were housed in individually in polypropylene cages
in a ventilated room (air cycles: 15/min; 70:30 exchange
ratio) under an ambient temperature of 22±2°C and 40–
65% relative humidity, with a 12-h light/dark artificial
photoperiod. They were provided with food (Nutrilab
Rodent, Tetragon Chemie Pvt Ltd, India) and purified
water ad libitum. All the animals were acclimatized at
least for 7 days to the laboratory conditions prior to ex-
perimentation. Guidelines of “Guide for the Care and
Use of Laboratory Animals” (Institute of Laboratory
Animal Resources, National Academic Press 1996; NIH
publication number #85-23, revised 1996) were strictly
followed throughout the study. Institutional Animal Eth-
ical Committee (IAEC), Sri Ramachandra University,
Chennai, India approved the study (IAEC/XIX/SRU/133/
2010).
Acute oral toxicity study
The acute oral toxicity test was performed following the
guidelines of Organization for Economic Co-operation
and Development (OECD) for testing of chemicals, TG
423 (adopted – December, 2001) with minor modifica-
tions [13]. Six female rats (nulliparous and non-
pregnant; 140-160g body weight) were randomised into
two groups (3 per group) viz., control and test groups.
Control group received 0.5% carboxy methyl cellulose
(prepared in double distilled water) as vehicle at a dose
volume of 10ml/kg b. wt. whilst the test group received
single oral dose of 2000 mg/kg b. wt. of NK (10ml/
kg b. wt. in 0.5% CMC) via gastric intubation. All theexperimental animals were observed for mortality and clin-
ical signs of toxicity (general behaviour, respiratory pattern,
cardiovascular signs, motor activities, reflexes and changes
in skin and fur texture) at 30 min, 1, 2 and 4 hours and
thereafter once a day for the next 14 days following vehicle
or NK administration. Body weights were recorded once a
week. On day 15, the overnight fasted animals (water
allowed) were euthanized using CO2 euthanasia chamber
and subjected to gross pathological examination of all the
major internal organs such as brain, heart, lung, liver, kid-
ney, spleen, adrenals and sex organs. LD50 cut-off value of
NK was determined in accordance with Globally Harmo-
nised System of Classification and Labelling of chemicals
[14].
Repeated dose 28-day oral toxicity study
A 28-day repeated oral toxicity study was performed
according to the OECD guideline, TG 407 (Revised - 18
December 2007) with minor modifications [15]. In
Siddha practice, 3g/day of NK was recommended for the
treatment of vitiligo in adult humans. The rat dose of
270mg/kg was arrived from the human dose based on
body surface area conversion [16]. In the present study,
NK was administered at three dose levels i.e., at 300, 600
and 900 mg/kg/day. Both sexes of Sprague Dawley rats
(140-160g) were divided into 6 groups with 10 animals
(5 males + 5 females) in each. Group I served as control
and received 0.5% CMC as vehicle orally via gastric in-
tubation at a dose volume of 10 ml/kg b. wt. Group II,
III and IV received NK at 300, 600 and 900 mg/kg/day,
p.o, respectively (10ml/kg b. wt. in 0.5% CMC), for a
period of 28 days via gastric intubation. In order to de-
termine the reversibility or recovery from toxic effects, if
any, the satellite groups were preset. Group V served as
satellite control (received vehicle) and group VI served
as treatment satellite group which received NK at 900
mg/kg/day, p.o for a period of 28 days. The satellite
groups were scheduled for follow-up observations for
the next 14 days without vehicle or NK administration.
All the experimental animals were observed for mor-
tality and morbidity twice a day, till the completion of
treatment. Clinical observations were made once daily to
detect signs of toxicity, preferably at the same time(s) in
each day (1h after vehicle or NK administration). The
focus of the observations was the same as described
above for the acute toxicity study. Body weights of the
animals were recorded once in a week. The amounts of
food and water given and their remnants on the next
day were measured to calculate the difference, which
was regarded as daily consumption and the data were
expressed as 7 days cumulative value.
At the end of the stipulated treatment period, the
overnight fasted (water allowed) animals were anaesthe-
tized, blood samples were collected by retro-orbital
Table 2 Secondary metabolites in Nuna kadugu
Secondary metabolites Nuna kadugu
mg/g extract %w/w
Tannins 2.34 ± 0.86 0.23±0.08
Total phenols 5.60 ± 2.11 0.56±0.02
Flavonoids 1.74 ± 0.67 0.17±0.07
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chemical analysis) and non-heparinised tubes (for serum
electrolytes). Haematological parameters such as haemo-
globin (HGB), red blood cell count (RBC), white blood
cell count (WBC), Hematocrit (HCT), platelet count
(PLT), mean corpuscular volume (MCV), mean corpus-
cular hemoglobin (MCH), mean corpuscular haemoglo-
bin concentration (MCHC), mean platelet volume
(MPV), Plateletcrit (PCT) and red cell indices were mea-
sured using fully automated haematology analyzer (PE
6000). Plasma biochemical parameters such as glucose,
total cholesterol (TC), triglycerides (TG), total protein
(TP), albumin, serum glutamic oxaloacetic transaminase
(SGOT), serum glutamic pyruvic transaminase (SGPT),
lactate dehydrogenase (LDH), alkaline phosphatase
(ALP), γ-glutamyl transpeptidase (γ-GT), bilirubin,
creatinine (CRE) and blood urea nitrogen (BUN) were
measured using diagnostic kits (Accurex, India) in a
semi-automatic biochemical analyser (Star 21plus, India).
Serum electrolytes such as sodium, potassium, chloride,
total calcium and pH were estimated in a fully auto-
mated electrolyte analyzer (Cornley acculyte-5P, India).
Histopathology
Necropsy was done in all animals on day 29 except the
satellite groups for which it was done on day 42. After
blood collection, all the animals were euthanized for
gross pathological examinations of all major internal
organs. Organs such as brain, eyes, spinal cord, lymph
nodes lung (right and left), prostate, thyroid gland, heart,
stomach, liver, kidney, adrenals, thymus, spleen, intestine,
muscle, bone, ovary, uterus, testis and urinary bladder
were collected from all the animals for histopathology.
The organs such as brain, heart, liver, spleen, kidneys,
adrenals, thymus, testis/ovaries, epididymis were weighed
and relative organ weights were calculated. However, it is













Note: S.No – Serial number; NK- Nuna Kadugu; + −mild, ++ − moderate,+++ −
high, – - absent.the control and high dose group initially, if any histo-
patholgical findings were observed with high dose group,
the low and mid dose groups were to be studied. The
organs were fixed in 10% neutral buffered formalin,
trimmed and a 5μ thickness of tissue sections were
stained with hematoxylin and eosin for histopathological
investigation.
Statistical analysis
Data were expressed in mean ± standard error mean
(SEM). Mean difference between the control and treat-
ment groups were analysed by Student ‘t’ test for acute
toxicity and one way ANOVA followed by Tukey’s mul-
tiple comparison as posthoc test for 28-day repeated




Phytochemical qualitative screening of NK showed the
presence different constituents like phenol, tannins, fla-
vones and quinines (Table 1). Quantitative presence of
total phenol, tannins and flavonoids contents of NK
were found to be 0.56, 0.23 and 0.17% w/w, respectively
(Table 2). Aflatoxins (B1, B2, G1 and G2) and heavy
metals (lead, cadmium, mercury and arsenic) contents
(Table 3) were found to be within the permissible limits











Lead 0.34 10 ppm
Cadmium 0.02 0.3 ppm
Mercury 0.04 1 ppm
Arsenic ND 3 ppm
ND: Not detected.
Figure 2 Effect of Nuna kadugu on body weight in control and
NK rats - Acute oral toxicity study. Note: Values expressed as
mean ± SEM (n=3).
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and Family Welfare, Government of India [17]. HPTLC
chromatogram of NK and photo documentation at 254
nm (Figure 1) revealed 7 peaks in the given chromato-
graphic condition.
Acute oral toxicity study
There were no treatment related death or signs of tox-
icity developed in both the control and NK treated ani-
mals throughout the study. No significant difference in
body weight gain was also observed (Figure 2). Further,
there were no gross pathological abnormalities in both
the groups. Thus the LD50 value was found to be greater
than 2000mg/kg b.wt. With reference to the Globally
Harmonised System of Classification and Labelling of
chemicals, Nuna Kadugu can be classified as Category
−5 and this provides direct relevance for protecting
human and animal health.
Repeated oral toxicity study
There were no treatment-related toxicity signs and mor-
tality observed in both sexes of rats treated at 300, 600
and 900 mg/kg orally for a period of 28 days and in the
satellite group of rats. No significant difference in body
weight gain was observed between control and treated
groups during the study (Table 4). Feed and water con-
sumption of NK treated groups were found to beFigure 1 HPTLC Fingerprint of Nuna Kadugu.insignificant in both the sexes when compared to the
0.5% CMC treated rats (Table 5 and 6). Hematological
parameters such as haemoglobin, red blood cells, white
blood cells, platelet count, mean corpuscular volume,
mean corpuscular haemoglobin, mean corpuscular
haemoglobin concentration, mean platelet volume and
red cell indices were found to be well within the clinical
range of rats [18] in experimental groups (Table 7). There
were no significant difference in plasma biochemical pro-
file such as glucose, total cholesterol, triglycerides, total
Table 4 Effect of Nuna kadugu on body weight gain in experimental rats - repeated oral toxicity study
Treatment Sex (g)
1st Week 2st Week 3st Week 4st Week 5th Week 6th Week
Control (0.5% CMC) M(n=5) 156.20±6.78 171.60±12.41 183.80±15.09 187.60±14.26
F (n=5) 155.4±10.3 157±7.75 166.6±4.80 169.6±4.54
MF(n=10) 155.8±5.82 164.3±7.32 175.2±8.00 178.6±7.67
NK (300 mg/kg p.o/day) M(n=5) 159.2±6.64 178.6±10.67 189.4±14.7 193.6±13.92
F (n=5) 143.0±2.16 148.4±3.64 157.4±3.45 160.0±3.49
MF(n=10) 151.10±4.26 163.50±7.32 173.40±8.90 176.80±8.78
(600 mg/kg p.o/day) M(n=5) 144.0±10.46 163.2±9.52 166.6±10.29 177.00±14.90
F (n=5) 142.40±10.27 159.40±11.85 163.00±10.13 177.80±11.06
MF(n=10) 143.20±6.89 161.30±7.19 164.80±6.83 177.40±8.74
(900 mg/kg p.o/day) M(n=5) 149.00±8.91 168.60±10.34 190.00±12.12 195.20±12.24
F (n=5) 139.60±5.23 146.80±4.67 157.20±6.86 161.60±6.99
MF(n=10) 144.3±5.11 157.7±6.46 173.6±8.54 178.40±8.68
Satellite group
Control (0.5% CMC) M(n=5) 141.00±12.54 164.80±16.47 169.80±17.46 174.60±17.57 178.40±20.52 185.00±18.43
F (n=5) 139.80±3.63 147.80±4.91 147.80±4.30 148.60±4.17 155.80±2.70 160.40±2.78
MF(n=10) 140.4±6.15 156.3±8.66 158.8±9.23 161.6±9.55 167.1±10.46 172.7±9.69
NK (900 mg/kg p.o/day) M(n=5) 152.6±11.56 170.2±12.50 181.2±8.25 179.6±13.95 182.2±12.85 188.2±9.68
F (n=5) 149.60±8.46 164.80±8.35 173.00±11.18 176.00±10.78 179.00±9.55 178.60±12.75
MF(n=10) 151.1±6.77 167.5±7.14 177.1±6.69 177.8±8.33 180.6±7.56 183.4±7.77
Values expressed as mean ± SEM; g – gram; Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
Table 5 Effect of Nuna kadugu on feed intake in experimental rats - repeated oral toxicity study
Treatment Sex (g)
1st Week 2st Week 3st Week 4st Week 5th Week 6th Week
Control (0.5% CMC) M(n=5) 80.60±3.61 82.20±7.44 89.40±7.86 101.00±1.64
F (n=5) 83.40±6.08 90.00±5.42 87.00±6.94 90.20±11.06
MF(n=10) 82.00±3.37 86.10±4.5 88.20±4.96 95.60±5.57
NK (300 mg/kg p.o/day) M(n=5) 93.40±8.76 88.60±9.09 88.80±9.4 93.60±6.71
F (n=5) 76.20±2.71 81.60±4.41 87.40±4.01 97.00±7.84
MF(n=10) 84.80±5.19 85.10±4.90 88.10±4.86 95.30±4.90
(600 mg/kg p.o/day) M(n=5) 87.40±5.64 93.00±4.60 92.80±4.12 96.60±5.27
F (n=5) 73.40±4.98 78.60±4.32 85.80±4.6 92.80±3.81
MF(n=10) 80.40±4.24 85.80±3.82 89.30±3.16 94.70±3.13
(900 mg/kg p.o/day) M(n=5) 79.20±4.07 76.00±3.7 79.80±4.19 97.60±2.36
F (n=5) 85.80±11.83 92.80±8.76 102.00±5.30 90.60±11.38
MF(n=10) 82.50±6.00 84.40±5.30 90.90±4.88 94.10±5.60
Satellite group
Control (0.5% CMC) M(n=5) 81.80±7.79 86.20±9.47 85.80±9.97 80.80±8.80 100.60±8.49 99.40±14.08
F (n=5) 82.00±7.13 89.40±5.87 92.20±1.46 109.80±1.02 98.00±10.21 99.20±7.62
MF(n=10) 81.90±4.98 87.80±5.28 89.00±4.87 95.306.39± 99.30±6.28 99.30±7.55
NK (900 mg/kg p.o/day) M(n=5) 82.40±6.93 89.00±7.50 82.00±5.02 103.60±4.74 98.00±8.63 99.20±6.88
F (n=5) 81.40±5.99 81.20±3.71 93.80±4.76 91.00±9.73 100.40±3.88 99.80±9.44
MF(n=10) 81.90±4.32 85.10±4.15 87.90±5.02 97.30±5.52 99.20±4.48 99.50±5.51
Values expressed as mean ± SEM; g – gram; Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
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Table 6 Effect of Nuna kadugu on water consumption in experimental rats - repeated oral toxicity study
Treatment Sex (ml)
1st Week 2st Week 3st Week 4st Week 5th Week 6th Week
Control (0.5% CMC) M(n=5) 100.80±12.45 101.00±15.37 100.40±6.96 100.80±11.34
F (n=5) 98.40±5.53 101. 00±11.05 101.80±12.68 101.40±13.95
MF(n=10) 99.60±6.43 101.00±8.92 101.10±6.82 101.10±8.48
NK (300 mg/kg p.o/day) M(n=5) 99.40±11.42 100. 20±9.61 101.20±16.83 100.60±13.67
F (n=5) 101.60±5.71 101.40±11.28 100.60±9.09 101.60±11.51
MF(n=10) 100.50±6.03 100.80±6.99 100.90±9.02 101.10±8.42
(600 mg/kg p.o/day) M(n=5) 98.80±11.89 101.80±9.05 101.00±19.24 100.80±14.37
F (n=5) 100.00±7.29 100.80±8.00 102.20±17.30 100.40±11.21
MF(n=10) 99.40±6.58 101.30±5.70 101.60±12.20 100.60±8.59
(900 mg/kg p.o/day) M(n=5) 99.80±9.61 100.40±5.35 100.20±9.44 98.80±7.00
F (n=5) 100.20±12.48 99.80±6.97 99.60±6.10 101.20±16.49
MF(n=10) 100.00±7.43 100. 10±4.14 99.90±5.30 100.00±8.45
Satellite group
Control (0.5% CMC) M(n=5) 101.60±8.35 102.60±7.12 100.80±15.63 102.40±13.55 101.40±10.62 100.40±19.44
F (n=5) 99.40±4.15 100.20±5.84 100.00±10.43 99.00±5.55 100.40±8.44 101.60±18.25
MF(n=10) 100.50±4.41 101.40±4.36 100.40±8.86 100.70±6.93 100.90±6.40 101.00±12.57
NK (900 mg/kg p.o/day) M(n=5) 101.60±8.39 101.40±10.63 101.60±14.66 101.20±4.04 102.40±11.78 101.60±10.80
F (n=5) 99.40±13.01 99.80±8.26 100.60±11.29 101.60±11.71 101.00±14.32 102.20±12.29
MF(n=10) 100.50±7.31 100.60±6.35 101.10±08.72 101.40±5.84 101.70±8.74 101.90±7.71
Values expressed as mean ± SEM; ml – milleliters; Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control
group.
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peptidase, bilirubin, lactate dehydrogenase, creatinine,
blood urea nitrogen (Table 8) observed between control
and treated groups. The levels of liver marker enzymes
like SGOT and SGPT were found to be well within the
clinical range of rats [18] in NK treated groups (Table 8).
Serum electrolytes such as sodium, potassium, chloride,
total calcium and pH were found to be normal between
the experimental groups (Table 9). There were no signifi-
cant differences in organ and relative organ weight of
brain, heart, liver, spleen, kidneys, adrenals and testis/
ovaries recorded between the control and NK groups
(Table 10 and 11). In our study, we performed hisopatho-
logical examinations in control and high dose group -
brain, liver, lung (right and left), prostate, spleen, heart,
spinal cord, lymph nodes, kidney, adrenals and other
organs and they were revealed no abnormalities
(Table 12). Hence we didn’t performed histopathology
examination of low and mid dose groups. Representative
histopathological photographs of brain, eyes, spinal cord,
lung, lymph nodes thyroid gland, heart, stomach, liver,
kidney, adrenals, thymus, spleen, intestine, muscle, bone,
ovary, uterus, testis and urinary bladder of control, high
dose and satellite groups (Fig not shown). There were no
hematological, biochemical and histoptahological altera-
tions observed with NK administration even at 900 mg/
kg/day in rats for a period of 28 days compared tocontrol. The No-Observed Adverse Effect Level
(NOAEL) of NK was estimated to be greater than 900
mg/kg/day in rats. Hence, it can be concluded that Nuna
Kadugu is safe for oral administration.
Discussion
Herbal medicines have attained greater importance as an
alternative to conventional therapy. To optimize the safe
use of a plant-based medicine, one should take into ac-
count their historical applications on humans and ani-
mals as well as toxicity evaluation of the medicinal herbs
and their active components [19]. Many screening meth-
ods are employed to determine the safety and efficacy of
these herbal medicines and also to establish the active
component of the herbal products [20]. Siddha system
of medicine is an ancient medical system of Dravidian
origin which is prevalent mainly in Southern parts of
India, especially in Tamil Nadu. Nuna (Morinda pubes-
cens), is a medicinal herb used in the treatment of viti-
ligo by many Siddha practitioners in Tamil Nadu.
However, the scientific validation of its safety and effi-
cacy has not been established so far. The present study
gives detailed information on the toxicological profile of
Nuna Kadugu by acute and repeated oral toxicity studies
in rats.
Since NK is in clinical use for vitiligo treatment for
more than 10 years, a limit test was performed in acute
Table 7 Effect of Nuna kadugu on hematological parameters in experimental rats - repeated oral toxicity study
Treatment Sex Hematological parameters
WBC (103/uL) RBC(106/uL) Hgb (%) HCT (%) MCV (fL) MCH(pg) MCHC(g/dl)
Control (0.5% CMC) M(n=5) 11.28±3.69 6.73±1.21 13.52±1.93 33.54±6.88 48.94±1.46 21.10±2.30 43.84±5.80
F (n=5) 18.28±1.27 6.83±1.35 16.48±0.64 35.74±7.15 53.60±2.03 36.42±16.08 36.48±2.89
MF(n=10) 15.97±2.01 6.39±0.89 14.85±1.11 33.01±4.81 50.81±1.53 29.30±8.00 39.95±4.46
NK (300 mg/kg p.o/day) M(n=5) 12.12±2.39 6.10±0.99 13.02±1.88 30.92±5.18 50.80±0.75 21.82±1.66 43.28±3.57
F (n=5) 13.50±1.89 7.69±0.77 14.10±1.20 38.80±3.62 49.70±1.32 19.48±0.65 36.681.84±
MF(n=10) 12.81±1.45 6.89±0.65 13.56±1.07 34.86±3.25 50.25±0.74 20.65±0.93 44.02±3.59
(600 mg/kg p.o/day) M(n=5) 12.68±2.39 6.54±0.29 13.20±0.82 33.40±1.24 48.54±4.69 19.76±0.72 44.82±4.15
F (n=5) 14.08±1.35 8.03±0.58 15.64±2.01 40.08±3.40 45.54±3.01 19.52±1.20 46.50±5.15
MF(n=10) 13.38±1.32 7.28±0.40 14.42 ±1.10 36.74±2.04 47.04±2.68 19.64±0.66 45.43±4.26
(900mg/kg p.o/day) M(n=5) 17.36±1.26 6.68±1.40 15.40±1.51 30.96±7.05 48.54 ±2.18 22.10±2.08 42.46±2.51
F (n=5) 14.14±1.46 7.24±0.67 16.46±1.96 33.18±2.70 45.64±2.17 23.80±1.82 45.78±4.29
MF(n=10) 15.75±1.05 6.96±0.74 15.93±1.18 32.07±3.58 47.09±1.53 22.95±1.33 44.12±2.41
Satellite group
Control (0.5% CMC) M(n=5) 18.18±2.30 8.67±0.55 18.48±0.90 42.82±1.73 47.08±1.97 19.48±0.57 40.94±2.13
F (n=5) 12.18±2.11 5.19±0.96 14.22±1.95 26.48±5.90 50.02±1.54 29.72±5.70 60.34±10.29
MF(n=10) 15.18±1.78 6.93±0.78 16.35±1.24 34.65±3.98 48.55±1.28 24.60±3.20 50.64±6.71
NK (900 mg/kg p.o/day) M(n=5) 15.88±0.90 8.78±0.38 15.60±1.03 42.74±2.32 46.16±3.17 18.24±1.07 45.16±3.05
F (n=5) 8.84±1.26 6.63±1.14 14.42±2.22 33.46±6.08 50.10±0.77 23.30±1.67 42.36±3.60
MF(n=10) 12.36±1.38 7.70±0.67 15.01±1.17 38.10±3.44 48.13±1.67 20.77±1.26 43.76±2.27
Treatment Sex Hematological parameters
RDW-CV (%) PLT (103/uL) MPV (fL) PDW (%) PCT (%) P-LCR (%)
Control (0.5% CMC) M(n=5) 14.32±0.60 324.80±57.03 10.00±0.37 9.30±0.24 0.18±0.02 20.64±2.01
F (n=5) 14.16±0.24 386.20±16.74 10.84±0.19 8.98±0.22 0.17±0.01 26.48±1.15
MF(n=10) 14.15± 0.33 372.90± 36.83 10.68 ± 0.19 8.65 ± 0.25 0.17 ± 0.02 23.87 ± 1.22
NK (300 mg/kg p.o/day) M(n=5) 13.70±0.54 351.00±45.03 10.34±0.78 9.02±0.60 0.11±0.01 20.08±2.83
F (n=5) 13.54±0.70 393.40±74.87 10.62±0.39 9.34±0.52 0.11±0.01 22.80±1.24
MF(n=10) 13.62± 0.42 372.20± 41.79 10.48 ± 0.41 9.18± 0.38 0.11± 0.02 21.44± 1.53
(600 mg/kg p.o/day) M(n=5) 16.58±2.62 369.40±65.75 8.96±0.74 8.80±0.28 0.15±0.02 22.53±1.11
F (n=5) 14.04±0.38 377.40±66.43 10.52±0.21 8.88±0.24 0.15±0.02 20.66±1.33
MF(n=10) 15.31 ± 1.32 373.40± 44.08 9.71± 0.49 8.85± 0.19 0.15± 0.01 21.65± 1.62
(900mg/kg p.o/day) M(n=5) 13.46±1.10 378.00±4.32 8.56±1.39 9.56±0.39 0.13±0.03 19.98±1.30
F (n=5) 14.90±0.57 366.00±60.78 10.640.87± 8.30±0.63 0.16±0.02 20.22±1.57
MF(n=10) 14.18± 0.63 372.00± 28.79 9.60± 0.85 8.93±0.41 0.15± 0.02 20.10± 0.96
Satellite group
Control (0.5% CMC) M(n=5) 14.08±0.56 377.20±46.72 10.76±0.19 8.32±0.40 0.15±0.02 22.54±1.31
F (n=5) 13.86±0.89 369.20±29.87 10.44±0.42 8.70±0.22 0.20±0.08 25.18±1.51
MF(n=10) 13.97± 0.50 373.20±26.17 10.60±0.22 8.51±0.22 0.17±0.04 23.86±1.04
NK (900 mg/kg p.o/day) M(n=5) 15.70±1.34 373.60±39.33 10.56±0.76 7.98±0.51 0.11±0.01 28.20±0.86
F (n=5) 15.00±0.58 371.20±34.98 10.09±0.59 9.70±0.36 0.10±0.01 25.70±1.76
MF(n=10) 15.35± 0.70 372.40±24.82 10.32±0.46 8.84±0.41 0.11±0.01 26.95±1.01
Values expressed as mean ± SEM; n=10 (5/sex); Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
Haemoglobin (HGB), red blood cell count (RBC), white blood cell count (WBC), Hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), mean corpuscular haemoglobin concentration (MCHC).
Values expressed as mean ± SEM; Significance with Tukey’s test following one way ANOVA is indicated as *p < 0.05 and **p < 0.01 vs control group. Mean platelet
volume (MPV), Plateletcrit (PCT) and red cell indices, platelet (PLT), RDW – red blood cell distribution Width, PDW – Platelet distribution Width.
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Table 8 Effect of Nuna kadugu on biochemical parameters of experimental Sprague Dawley rats in repeated oral
toxicity study















Control (0.5% CMC) M(n=5) 128.90 ±12.51 88.01 ±5.69 45.18 ±8.56 4.63 ±0.28 2.27 ±0.13 30.40 ±4.04 33.92 ±3.38
F (n=5) 134.24 ±5.13 86.64 ±7.32 50.50 ±9.00 4.70 ±0.34 2.38 ±0.23 29.40 ±4.12 43.16 ±7.41
MF(n=10) 131.57±6.44 87.32±4.38 47.84±5.92 4.67±0.21 2.33±0.13 29.90±2.73 38.54±4.14
NK (300 mg/kg p.o/day) M(n=5) 131.16 ±9.57 87.98 ±10.81 51.20 ±11.66 4.90 ±0.13 2.43 ±0.15 29.92 ±5.31 43.83 ±6.02
F (n=5) 130.31 ±11.64 87.74 ±13.2 44.79 ±3.18 5.01 ±0.15 2.34 ±0.23 29.90 ±3.93 34.19 ±4.42
MF(n=10) 130.74±7.11 87.86±8.05 47.99±5.80 4.96±0.09 2.39±0.13 29.91±3.11 39.01±3.87
(600 mg/kg p.o/day) M(n=5) 128.35 ±12.39 89.26 ±3.32 50.57 ±1.53 4.82 ±0.27 2.22 ±0.29 29.10 ±3.69 40.99 ±4.52
F (n=5) 132.61 ±15.43 85.92 ±10.74 44.74 ±3.50 4.78 ±0.49 2.20 ±0.23 31.22 ±4.86 38.66 ±3.67
MF(n=10) 130.48±9.35 87.59±5.33 47.66±2.05 4.80±0.26 2.21±0.18 30.16±2.90 39.83±2.77
(900mg/kg p.o/day) M(n=5) 130.18 ±2.79 85.73 ±14.31 47.91 ±6.91 4.95 ±0.50 2.33 ±0.30 30.20 ±4.21 38.56 ±6.79
F (n=5) 130.58 ±13.84 88.77 ±14.81 47.05 ±5.99 4.66 ±0.28 2.24 ±0.13 31.08 ±6.96 41.00 ±8.08
MF(n=10) 130.38±6.66 87.25±9.72 47.48±4.31 4.80±0.28 2.28±0.15 30.64±3.84 39.78±4.99
Satellite group
Control (0.5% CMC) M(n=5) 134.32 ±8.85 89.59 ±10.96 47.55 ±3.73 4.92 ±0.32 2.34 ±0.25 31.14 ±1.17 39.68 ±4.37
F (n=5) 127.92 ±12.83 85.61 ±10.53 48.65 ±2.67 5.05 ±0.45 2.12 ±0.22 29.54 ±4.74 39.01 ±2.98
MF(n=10) 131.12±7.42 87.60±7.19 48.10±2.17 4.99±0.26 2.23±0.16 30.34±2.32 39.35±2.50
NK (900 mg/kg p.o/day) M(n=5) 131.55 ±4.12 87.57 ±5.61 46.79 ±5.22 4.80 ±0.31 2.20 ±0.13 24.96 ±4.73 39.88 ±4.38
F (n=5) 132.35 ±14.32 86.61 ±13.93 49.42 ±4.24 4.71 ±0.33 2.42 ±0.19 35.36 ±3.85 38.66 ±7.83
MF(n=10) 131.95±7.02 87.09±7.08 48.11±3.20 4.75±0.21 2.31±0.12 30.16±3.36 39.27±4.24











Control (0.5% CMC) M(n=5) 178.20±9.72 329.00±46.89 2.39±0.23 0.83±0.03 0.43±0.05 19.07±0.63
F (n=5) 180.60±12.33 286.80±51.41 2.11±0.14 0.90±0.03 0.31±0.03 20.18±1.43
MF(n=10) 179.40±7.41 307.90±33.55 2.25±0.13 0.87±0.02 0.37±0.03 19.63±0.76
NK (300 mg/kg .o/day) M(n=5) 179.60±16.64 307.22±18.45 2.12±0.19 0.54±0.27 0.28±0.02 19.06±3.10
F (n=5) 178.20±12.08 310.06±14.29 2.10±0.20 1.00±0.08 0.35±0.03 18.08±1.28
MF(n=10) 178.90±9.69 308.64±11.01 2.11±0.13 0.77±0.15 0.31±0.02 18.57±1.59
(600 mg/kg p.o/day) M(n=5) 181.40±7.28 306.74±16.29 2.03±0.23 0.84±0.05 0.34±0.04 18.56±2.11
F (n=5) 179.80±11.51 311.32±32.42 1.96±0.20 0.84±0.06 0.34±0.04 20.26±1.33
MF(n=10) 180.60±6.42 309.03±25.89 1.99±0.14 0.84±0.04 0.34±0.03 19.41±1.21
(900mg/kg p.o/day) M(n=5) 178.20±14.03 310.82±35.07 2.04±0.21 0.99±0.04 0.37±0.03 19.62±1.65
F (n=5) 183.60±8.59 306.64±31.52 2.13±0.22 0.97±0.02 0.30±0.03 18.55±2.00
MF(n=10) 180.90±7.81 308.73±35.56 2.09±0.14 0.98±0.02 0.33±0.02 19.09±1.24
Satellite group
Control (0.5% CMC) M(n=5) 180.60±10.13 288.66±20.91 2.01±0.25 0.92±0.06 0.32±0.03 19.88±0.86
F (n=5) 181.60±16.71 330.98±50.39 2.06±0.28 0.93±0.05 0.34±0.03 20.78±1.10
MF(n=10) 181.10±9.21 309.82±26.66 2.04±0.18 0.93±0.04 0.33±0.02 20.33±0.68
NK (900 mg/kg p.o/day) M(n=5) 180.20±13.43 310.80±33.66 2.28±0.29 0.96±0.13 0.38±0.04 21.21±2.33
F (n=5) 181.20±14.59 308.42±36.41 1.85±0.23 0.930.04± 0.31±0.03 20.48±1.60
MF(n=10) 180.70±9.35 309.61±23.38 2.06±0.19 0.94±0.06 0.35±0.03 20.85±1.34
Values expressed as mean ± SEM; Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group. SGOT –
Serum Glutamate oxaloacetate transaminase; SGPT – Serum Glutamate pyruvate transaminase.
Values expressed as mean ± SEM; n=10 (5/sex); Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
LDH – Lactate dehydrogenase; ALP- Alkaline Phosphatase; GGT- Gamma Glutamyl Transferase; BUN – Blood Urea Nitrogen.
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Table 9 Effect of Nuna kadugu on serum electrolytes of experimental Sprague Dawley rats in repeated oral toxicity
study
Treatment Sex Serum electrolytes (mmol/l)
Sodium Potassium Chloride Total Calcium pH
Control (0.5% CMC) M(n=5) 136.46±0.59 4.68±0.19 99.48±1.32 2.38±0.02 7.35±0.09
F (n=5) 140.09±0.86 4.06±0.10 100.94±1.95 2.45±0.02 7.42±0.13
MF(n=10) 138.28±0.78 4.37±0.14 100.21±1.14 2.42±0.02 7.39±0.08
NK (300 mg/kg p.o/day) M(n=5) 139.03±0.73 4.40±0.15 99.49±1.14 2.33±0.08 7.41±0.09
F (n=5) 137.76±0.31 4.02±0.08 99.20±0.49 2.47±0.02 7.40±0.06
MF(n=10) 138.39±0.43 4.21±0.10 99.34±0.59 2.40±0.05 7.40±0.05
(600 mg/kg p.o/day) M(n=5) 138.12±0.70 4.35±0.12 99.53±0.33 2.47±0.01 7.38±0.11
F (n=5) 138.03±1.04 4.08±0.12 100.27±0.53 2.38±0.03 7.39±0.05
MF(n=10) 138.07±0.59 4.21±0.09 99.90±0.32 2.42±0.02 7.39±0.06
(900mg/kg p.o/day) M(n=5) 142.58±1.20 4.23±0.13 102.82±1.09 2.41±0.02 7.40±0.09
F (n=5) 134.75±2.47 4.19±0.12 98.15±1.03 2.41±0.05 7.36±0.10
MF(n=10) 138.67±1.84 4.21±0.08 100.49±1.05 2.41±0.03 7.38±0.06
Satellite group
Control (0.5% CMC) M(n=5) 147.40±1.68 4.25±0.04 100.43±1.62 2.36±0.07 7.39±0.09
F (n=5) 132.23±6.90 4.19±0.05 101.02±1.62 2.44±0.07 7.39±0.04
MF(n=10) 139.82±4.19 4.22±0.03 100.73±1.09 2.40±0.05 7.39±0.04
NK (900 mg/kg p.o/day) M(n=5) 140.23±1.15 4.25±0.07 102.02±1.83 2.35±0.09 7.40±0.13
F (n=5) 139.57±0.98 4.20±0.08 99.79±3.32 2.42±0.07 7.40±0.15
MF(n=10) 139.90 ± 0.72 4.23± 0.05 100.90 ± 1.82 2.39± 0.05 7.40 ± 0.09
Values expressed as mean ± SEM; n=10 (5/sex); Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
Table 10 Effect of Nuna kadugu on organ weight of experimental Sprague Dawley rats in repeated oral toxicity study
Treatment Sex Organ Weight (gms)
Kidneys Adrenals Thymus Testis/Ovaries Epididymis
Control (0.5% CMC) M(n=5) 1.65±0.13 0.05±0.01 0.48±0.01 2.06±0.42 1.43±0.03
F (n=5) 1.34±0.13 0.04±0.00 0.48±0.03 0.08±0.02 -
MF(n=10) 1.49±0.10 0.04± 0.00 0.48±0.01 - -
NK (300 mg/kg p.o/day) M(n=5) 1.79±0.12 0.05±0.01 0.48±0.01 2.09±0.17 1.41±0.03
F (n=5) 1.35±0.04 0.05±0.01 0.49±0.02 0.32±0.02 -
MF(n=10) 1.57±0.09 0.05±0.00 0.48±0.01 - -
(600 mg/kg p.o/day) M(n=5) 1.61±0.10 0.04±0.00 0.47±0.02 1.96±0.19 1.47±0.03
F (n=5) 1.36±0.07 0.04±0.00 0.48±0.01 0.08±0.01 -
MF(n=10) 1.49±0.07 0.04±0.00 0.47±0.01 - -
(900mg/kg p.o/day) M(n=5) 1.64±0.14 0.04±0.00 0.47±0.01 2.22±0.38 1.49±0.03
F (n=5) 1.37±0.08 0.05±0.01 0.52±0.03 0.09±0.01 -
MF(n=10) 1.51±0.09 0.05±0.00 0.49±0.02 - -
Satellite group
Control (0.5% CMC) M(n=5) 1.51±0.12 0.05±0.01 0.46±0.02 1.98±0.43 1.41±0.03
F (n=5) 1.34±0.07 0.05±0.00 0.49±0.02 0.10±0.01 -
MF(n=10) 1.42±0.07 0.05±0.00 0.48±0.01 - -
NK (900 mg/kg p.o/day) M(n=5) 1.68±0.10 0.05±0.00 0.490.02 2.04±0.31 1.54±0.02
F (n=5) 1.35±0.05 0.05±0.00 0.51±0.03 0.12±0.00
MF(n=10) 1.51±0.08 0.05±0.00 0.50±0.02 1.98±0.43
Values expressed as mean ± SEM; n=10 (5/sex); Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
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Table 11 Effect of Nuna kadugu on relative organ weight of experimental Sprague Dawley rats in repeated oral
toxicity study
Treatment Sex Relative organ weight (g %)
Brain Heart Liver Spleen Kidney Adrenal Sex organs
Testis Ovaries
Control (0.5% CMC) M (n=5) 0.99±0.06 0.38±0.02 3.53±0.22 0.47±0.03 0.88±0.03 0.03±0.00 1.07±0.15 -
F (n=5) 1.05±0.04 0.42±0.43 4.21±0.35 0.49±0.02 0.79±0.08 0.02±0.00 - 0.05±0.01
MF (n=10) 1.02±0.03 0.40±0.02 3.87±0.23 0.48±0.02 0.84±0.04 0.02±0.00 - -
NK (300 mg/kg p.o/day) M (n=5) 0.97±0.08 0.41±0.01 3.70±0.14 0.54±0.11 0.93±0.06 0.02±0.00 1.12±0.15 -
F (n=5) 1.10±0.05 0.40±0.02 3.79±0.28 0.42±0.04 0.85±0.03 0.03±0.00 - 0.07±0.01
MF (n=10) 1.04±0.05 0.40±0.01 3.74±0.15 0.48±0.06 0.89±0.03 0.03±0.00 - -
(600 mg/kg p.o/day) M (n=5) 1.06±0.12 0.40±0.03 3.99±0.75 0.43±0.06 0.96±0.15 0.02±0.00 1.16±0.20 -
F (n=5) 1.00±0.04 0.39±0.03 3.45±0.12 0.38±0.03 0.77±0.03 0.02±0.00 - 0.05±0.01
MF (n=10) 1.03±0.06 0.40±0.02 3.72±0.37 0.40±0.03 0.86±0.08 0.02±0.00 - -
(900mg/kg p.o/day) M (n=5) 0.97±0.06 0.38±0.02 3.63±0.41 0.48±0.04 0.84±0.03 0.02±0.00 1.11±0.16 -
F (n=5) 1.14±0.04 0.40±0.01 3.90±0.19 0.52±0.06 0.85±0.02 0.03±0.00 - 0.06±0.01
MF (n=10) 1.05±0.05 0.39±0.01 3.76±0.22 0.50±0.03 0.84±0.02 0.03±0.00 - -
Satellite group
Control (0.5% CMC) M (n=5) 1.03±0.10 0.41±0.02 3.93±0.26 0.41±0.03 0.83±0.05 0.03±0.00 1.07±0.19 -
F (n=5) 1.08±0.04 0.36±0.01 3.91±0.25 0.46±0.05 0.84±0.04 0.03±0.00 - 0.07±0.01
MF (n=10) 1.05±0.05 0.39±0.01 3.92±0.17 0.44±0.03 0.83±0.03 0.03±0.00 - -
NK (900 mg/kg p.o/day) M (n=5) 0.99±0.04 0.41±0.04 4.06±0.27 0.49±0.03 0.89±0.04 0.03±0.00 1.07±0.12 -
F (n=5) 1.02±0.03 0.39±0.04 3.41±0.44 0.39±0.04 0.77±0.07 0.03±0.00 - 0.07±0.01
MF (n=10) 1.02±0.02 0.40±0.03 3.74±0.27 0.44±0.03 0.83±0.04 0.03±0.00 - -
Values expressed as mean ± SEM; n=10 (5/sex); Significance with Tukey’s test following one way ANOVA is evaluated as *p < 0.05 and **p < 0.01 vs control group.
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line 423 when there is information in support of low or
non-toxicity and immortality nature of the test material,
then the limit test at the highest starting dose level
(2000 mg/kg body weight) was conducted. There were
no mortality and toxicity signs observed at 2000mg/kg.
Nuna Kadugu can be classified under category-5 and
LD50 value was greater than 2000mg/kg in accordance
with Globally Harmonised System of Classification and
Labelling of chemicals and this provides us a direct rele-
vance for protecting human and animal health. There-
fore, it can be concluded that Nuna Kadugu when
administered at single dose is non-toxic and can be used
safely in oral formulations.
A 28-day repeated oral toxicity study was performed
followed OECD test guideline 407 (Revised 18 December
2007) in both male and female Sprague Dawley rats.
Since examination of clinical signs plays major role in
toxicological testing [21], mortality and morbidity were
recorded twice a day throughout the study. NK did not
produce any alterations in feed and water consumption
and this reveals that it did not adversely affect the basic
metabolic processes of the experimental animals. The
haemopoietic system serves as important target for toxic
chemicals and is a sensitive index for pathological condi-
tions both in humans and animals [22]. In the presentstudy, treatment with NK did not produce any alteration
in haematological parameters (i.e. RBC, WBC, haemo-
globin, haematocrit etc.), which indicate that NK did not
affect blood cells nor their production. Clinical biochem-
istry and hematological data holds significant role in de-
termining the toxicity induced by drugs [18].
Transaminases (SGOT and SGPT) are good indicators of
liver function and biomarkers to predict the possible
toxicity of drugs [23]. Any elevation pertaining to these
enzymes indicate their outflow into the blood stream
due to damage in liver parenchymal cells.
There were no changes in the SGPT and SGOT
levels which reveal that NK did not affect liver func-
tion/or metabolism. In the present study, there were no
treatment related abnormalities in renal function and
other biochemical parameters suggesting that NK is
non-toxic. Similarly, the serum electrolyte levels were
found to be well within the clinical range of rats which
reflects that NK has no adverse effect on ionic homeo-
stasis. Histopathological studies provide supportive evi-
dence for biochemical and haematological observations
[24]. The relative organ weights were found to be non-
significant between the control and NK treated rats.
No abnormality was recorded with respect to gross or
histopathological examinations of all organs examined.
Since there were no signs of toxicity with respect to
Table 12 Histopathological investigation of control and NK treated animals for 28 days
Tissue Treatment Male Female
Brain, Eyes Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Lung (right and left), Prostate,
Thyroid gland, Thymus
Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Spinal Cord, Lymph Nodes,
Muscle, Bone
Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Heart, Liver Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Stomach, Intestine Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Kidney, Adrenals, Urinary bladder Control (0.5% CMC) Normal Normal
NK (900 mg/kg p.o/day) Normal Normal
Satellite - NK (900 mg/kg p.o/day) Normal Normal
Sex organ (Testis/Epididymis) Control (0.5% CMC) Normal -
NK (900 mg/kg p.o/day) Normal -
Satellite - NK (900 mg/kg p.o/day) Normal -
Sex organ (Uterus /ovaries/) Control (0.5% CMC) - Normal
NK (900 mg/kg p.o/day) - Normal
Satellite - NK (900 mg/kg p.o/day) - Normal
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http://www.biomedcentral.com/1472-6882/12/190hematology, clinical chemistry, organ weight, gross and
histopathological examinations noted in NK satellite
group, it can be inferred that NK will not produce
delayed onset of toxicity. Based on these results, the
No Observed Adverse Effect Level (NOAEL) of “Nuna
Kadugu” is greater than 900 mg/kg/day.
Conclusion
In accordance with Globally Harmonised System of
Classification and Labelling of chemicals, NK can be
classified as Category 5. Based on 28 day repeated dose
toxicity study, NOAEL of NK is greater than 900 mg/kg/
day. The present investigation substantiates, at least in
part, the safety of NK, which was found to be in line
with the long history of its use in Siddha system of
medicine.
Competing interest
Authors declare that they have no competing interests.
Authors’ contributions
RSR designed and drafted the manuscript; NP, RS, HS, KTM performed the
experiment and assisted in manuscript preparation; RJP performed
pathology; JRV animals health monitoring, clinical signs assessment and
manuscript preparation; CSB designed the study; KM conceived the study, ST
coordinated the study. All authors read and approved the final manuscript.Acknowledgement
Authors acknowledge the Department of AYUSH, Ministry of Health and
Family Welfare, New Delhi, Govt of India, for funding the project. Authors
also express their thanks to Mr.Subramanian, Senior Research Officer, NIS,
Chennai, for helping in statistics and proof reading. Authors also express
thanks to Mrs.Gayathri, Senior Research Fellow, CEFT, SRU, for helping in
revising the manuscript.
Author details
1Department of Sirappu Maruthuvam, National Institute of Siddha, Tambaram
Sanatorium, Chennai 600 047, India. 2Centre for Toxicology and
Developmental Research (CEFT), Sri Ramachandra University, Ramachandra
Nagar, Chennai 600 116, India.
Received: 23 November 2011 Accepted: 3 October 2012
Published: 22 October 2012
References
1. Halder RM, Chappell JL: Vitiligo update. Semin Cutan Med Surg 2009,
28(2):86–92.
2. Das SK, Majumder PP, Chakraborty R, Majumdar TK, Haldar B: Studies on
vitiligo: Epidemiological profile in Calcutta, India. Genet Epidemiol 1985,
2:71–78.
3. Handa S, Kaur I: Vitiligo: Clinical findings in 1436 patients. J Dermatol
1999, 26:653–657.
4. Mathivanan N, Surendiran G: Chemical properties and biological activities of
Morinda spp, Proceedings of First National Symposium on Noni Research.
Hyderabad: Noni Phytochemical Research Programme World Noni Research
Foundation; 2006:40–47.
5. Annalakshmi-Manjanathi G: Amruth-The traditional health care bimonthly.
2003, 7(5):9–10.
Ramaswamy et al. BMC Complementary and Alternative Medicine 2012, 12:190 Page 13 of 13
http://www.biomedcentral.com/1472-6882/12/1906. Mathivanan N, Surendiran G, Srinivasan K, Malarvizhi K: Morinda pubescens
JE Smith (Morinda tinctoria Roxb) fruit extract accelerates wound healing
in rats. J Med Food 2006, 9(4):591–93.
7. Desai Nivas M, Gaikwad DK, Chavan PD: Antioxidant potential of Morinda
pubescens fruits. J Pharm Res 2011, 4(3):829–831.
8. Mudaliar KSM: Gunapadam – Part – I (Porut Panbu Nool), Siddha Materia
Medica (Medicinal Plants Division), First Edition. Chennai: Department of
Indian Medicine and Homoeopathy; 1936.
9. Harborne, et al: Harborne JB, Phytochemical methods, A guide to modern
techniques of plant analysis. Thirdth edition. New York: Chapman and Hall
Int. Ed; 1998.
10. McDonald S, Prenzler PD, Autolovich M, Robards K: Phenolic content and
antioxidant activity of olive extracts. Food Chem 2001, 73:73–84.
11. Schanderl SH: In Tannins and related phenolics. Methods in Food Analysis.
Edited by Joslyn MA. New York: Academic Press; 1970:701–724.
12. Chang C, Yang M, Wen H: Estimation of total flavonoid content in
propolis by two complementary colorimetric methods. J Food Drug Anal
2002, 10:178–182.
13. OECD: Guidelines for the Testing of Chemicals/Section 4: Health Effects Test No.
423: Acute Oral toxicity - Acute Toxic Class Method. Paris, France: Organization
for Economic Cooperation and Development; 2002.
14. OECD Forum for the Future., Organisation for Economic Co-operation and
Development: Advisory Unit on Multi-Disciplinary Issues. Expo 2000/OECD
Forum for the Future: 21st Century Technologies: balancing economic, social
and environmental goals: main issues and summary of the discussions of a
Conference held on 7th and 8th December at Schloss Krickenbeck, Germany.
Paris: OECD; 1998.
15. Organization for Economic Cooperation and Development;Guidelines for
the Testing of Chemicals/Draft Updated Test Guideline 407: Repeated Dose
28-Day Oral Toxicity Study in Rodents. 2008.
16. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE: Quantitative
comparison of toxicity of anticancer agents in mouse, rat, hamster, dog,
monkey and man. Cancer Chemother Rep 1 1966, 50(4):219–244.
17. Saper RB, Kales SN, Thuppil V: Metal Content in Ayurvedic Medicines—
Reply. JAMA 2009, 301(3):272.
18. Petterino C, Argentino-Storino A: Clinical chemistry and haematology
historical data in control Sprague–Dawley rats from pre-clinical toxicity
studies. Exp Toxicol Pathol 2006, 57:213–219.
19. Mukinda JT, Syce JA: Acute and chronic toxicity of the aqueous extract of
Artemisiaa fra in rodents. J Ethnopharmacol 2007, 112:138–144.
20. Sim KT, Sri Nurestri AM, Sinniah SK, Kim KH, Norhanom AW: Acute oral
toxicity of Pereskia bleo and Pereskia grandiofolia in mice. Pharmacogn
Mag 2010, 6:67–70.
21. Stevens KR, Mylecraine L: Issues in chronic toxicology. In Principles and
Methods of Toxicology. thirdth edition. Edited by Hayes AW. New York:
Raven Press; 1994:673.
22. Adeneyea AA, Ajagbonnab OP, Adelekec TI, Bellod SO: Preliminary toxicity
and phytochemical studies of the stem bark aqueous extract of
Musanga cecropioides in rats. J Ethnopharmacol 2006, 105:374–379.
23. Hilaly JE, Israili ZH, Lyouss B: Acute and chronic toxicological studies of
Ajuva Iva in experimental animals. J Ethnopharmacol 2004, 91:43–50.
24. Matsuzawa T, Nomura M, Yonezawa H, Unno T: Selection of appropriate
parameters, use of a quality control concept, and suitable statistical
analyses for clinical pathology examination of animals in toxicity studies:
results of a current survey by the Japanese Pharmaceutical
Manufacturers Association. Comp Haematol Int 1995, 5:196–200.
doi:10.1186/1472-6882-12-190
Cite this article as: Ramaswamy et al.: Acute toxicity and the 28-day
repeated dose study of a Siddha medicine Nuna Kadugu in rats. BMC
Complementary and Alternative Medicine 2012 12:190.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
